The Board incorrectly interpreted Section 311(b)’s “prior art consisting of patents or printed publications” to encompass applicant admitted prior art, but such art may be relevant as an admission. Concluding that the Patent Trial and Appeal Board incorrectly considered applicant admitted prior art (AAPA) in its review of a Qualcomm’s integrated circuit patent in a…
The Board’s inter partes review decision declaring unpatentable a system that monitors and controls remote devices was reversed. Based on improper claim construction, the U.S. Court of Appeals for the Federal Circuit has reversed a decision by the Patent Trial and Appeal Board declaring a patent system that monitors and controls remote devices as unpatentable….
The PTAB improperly found that the patent is unpatentable in view of the prior art. Concluding that the Patent Trial and Appeal Board improperly construed certain claims in a patent for memory system circuits owned by Innovative Memory Systems, Inc. in an inter partes review filed by Micron Technology, Inc., the U.S. Court of Appeals…
Patent claims relating to a virus-protection software to filter e-mail and electronic files are merely generic computer functions and not covered by a patent-eligible concept, the U.S. Court of Appeals for the Federal Circuit has ruled. In affirming a decision of the federal district court in Seattle, Washington to dismiss the patent infringement case brought…
The U.S. Court of Appeals for the Federal Circuit has affirmed a $139.8 million jury verdict in favor of Sprint Communications against Time Warner for infringement of five Sprint patents related to VoIP technology. The appeals court concluded that the district properly admitted evidence relating to the jury verdict in an earlier, related case brought…
Concluding that the asserted claims of patents relating to dosing and administration of the drug Copaxone used to treat multiple sclerosis are obvious, the U.S. Court of Appeals the Federal Circuit has affirmed a decision by the federal district court in Delaware invalidating the patents, handing a major victory to generic drug manufacturers. The Federal…
